Reuters
09 Jul 2026, 06:12 UTC · 2h ago
AstraZeneca-Ionis drug fails to meet main goal in late-stage heart disease trial
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
09 Jul 2026, 06:12 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
AstraZeneca's drug Wainua failed to meet its primary endpoint of reducing cardiovascular deaths and recurring heart problems in a late-stage trial. — Failure of a late-stage clinical trial typically leads to immediate valuation drops for the involved companies due to lost revenue potential.
-0.80The drug Wainua was developed in partnership with Ionis. — The failure negatively affects the pipeline and potential royalty/milestone streams for the partner company, Ionis.
-0.30Which stocks this story touches
Late-stage trial of the drug Wainua failed to meet its primary endpoint for reducing cardiovascular deaths.
Continue reading
6 related stories
Top 2 movers · tap to explore
Partnered drug Wainua failed to meet its main goal in a late-stage clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
1h ago
